<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45654">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511912</url>
  </required_header>
  <id_info>
    <org_study_id>RELIEVE-HF I</org_study_id>
    <nct_id>NCT02511912</nct_id>
  </id_info>
  <brief_title>REducing Lung Congestion Symptoms Using thE V-wavE Shunt in Advanced Heart Failure</brief_title>
  <acronym>RELIEVE-HF</acronym>
  <official_title>REducing Lung Congestion Symptoms Using thE V-wavE Shunt in Advanced Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>V-Wave Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>V-Wave Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized, open label, single-arm multi-center study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, open label, single-arm multi-center study evaluating
      the perfromance and safety of the V-Wave interatrial shunt when implanted in chronic heart
      failure patients with both reduced and preserved ejection fraction.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Related Major Adverse Cardiac and Cerebrovascular Events (MACCE) including death, stroke, peripheral embolization and myocardial infarction occurring within 6-months post-procedure</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in six (6) minute walk test distance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Major Adverse Cardiac and Cerebrovascular Events (MACCE)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>V-Wave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.
The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>V-Wave</intervention_name>
    <description>The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.</description>
    <arm_group_label>V-Wave</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic (&gt;6 months) ischemic or non-ischemic cardiomyopathy, ACC/AHA Stage C, NYHA
             Class III or ambulatory Class IV heart failure, Receiving optimal guideline directed
             medical therapy as defined by ACC/AHA guidelines

          2. Patient or legally acceptable representative, signed a written informed consent form
             (ICF) to participate in the study

          3. Ejection Fraction â‰¥ 15%

        Exclusion Criteria:

          1. Right Heart Failure

          2. Right Atrial Pressure (RAP) &gt; Left Atrial Pressure (LAP)

          3. Congenital heart disease

          4. Severe pulmonary hypertension

          5. Severe restrictive or obstructive lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rotem Katzenellenbogen</last_name>
    <role>Study Director</role>
    <affiliation>V-Wave Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rotem Katzenellenbogen</last_name>
    <phone>972-77-316-8554</phone>
    <email>rotem@vwavemedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>V-Wave Ltd.</name>
      <address>
        <city>Or-Akiva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rotem Katzenellenbogen</last_name>
      <phone>972-77-316-8554</phone>
      <email>rotem@vwavemedical.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 27, 2015</lastchanged_date>
  <firstreceived_date>June 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
